P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000972440.80732.55 |
| _version_ | 1797281633911439360 |
|---|---|
| author | Sylvain Choquet Andrew Clark Cécile Renard Ben Uttenthal Sridhar Chaganti Ralf Ulrich Trappe Patrizia Comoli Xinyuan Duan Baodong Xing Charley Wu Laurence Gamelin Jan-Henrik Terwey Anke Friedetzky Daan Dierickx |
| author_facet | Sylvain Choquet Andrew Clark Cécile Renard Ben Uttenthal Sridhar Chaganti Ralf Ulrich Trappe Patrizia Comoli Xinyuan Duan Baodong Xing Charley Wu Laurence Gamelin Jan-Henrik Terwey Anke Friedetzky Daan Dierickx |
| author_sort | Sylvain Choquet |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:00:15Z |
| format | Article |
| id | doaj.art-aa027855236c4b1ea54bea970adf8954 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:00:15Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-aa027855236c4b1ea54bea970adf89542024-03-03T03:25:27ZengWileyHemaSphere2572-92412023-08-017e807325510.1097/01.HS9.0000972440.80732.55202308003-01284P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPESylvain Choquet0Andrew Clark1Cécile Renard2Ben Uttenthal3Sridhar Chaganti4Ralf Ulrich Trappe5Patrizia Comoli6Xinyuan Duan7Baodong Xing8Charley Wu9Laurence Gamelin10Jan-Henrik Terwey11Anke Friedetzky12Daan Dierickx131 Hôpital de la Pitié-Salpêtrière, Paris, France2 NHS Greater Glasgow and Clyde, Glasgow, United Kingdom3 Institut d’Hématologie et d’Oncologie Pédiatrique, Lyon, France4 Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom5 University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom6 DIAKO Hospital Bremen, Bremen, Germany7 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States9 Atara Biotherapeutics Switzerland GmbH, Zug, Switzerland9 Atara Biotherapeutics Switzerland GmbH, Zug, Switzerland10 University Hospitals Leuven, Leuven, Belgiumhttp://journals.lww.com/10.1097/01.HS9.0000972440.80732.55 |
| spellingShingle | Sylvain Choquet Andrew Clark Cécile Renard Ben Uttenthal Sridhar Chaganti Ralf Ulrich Trappe Patrizia Comoli Xinyuan Duan Baodong Xing Charley Wu Laurence Gamelin Jan-Henrik Terwey Anke Friedetzky Daan Dierickx P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE HemaSphere |
| title | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
| title_full | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
| title_fullStr | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
| title_full_unstemmed | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
| title_short | P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE |
| title_sort | p1388 effectiveness and safety outcomes in patients with ebv ptld treated with allogeneic ebv specific t cell immunotherapy tabelecleucel under an expanded access program in europe |
| url | http://journals.lww.com/10.1097/01.HS9.0000972440.80732.55 |
| work_keys_str_mv | AT sylvainchoquet p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT andrewclark p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT cecilerenard p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT benuttenthal p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT sridharchaganti p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT ralfulrichtrappe p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT patriziacomoli p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT xinyuanduan p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT baodongxing p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT charleywu p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT laurencegamelin p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT janhenrikterwey p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT ankefriedetzky p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope AT daandierickx p1388effectivenessandsafetyoutcomesinpatientswithebvptldtreatedwithallogeneicebvspecifictcellimmunotherapytabelecleucelunderanexpandedaccessprogramineurope |